Transgenic Adenocarcinoma of the Mouse Prostate: A Validated Model for the Identification and Characterization of Molecular Targets and The Evaluation of Therapeutic Agents
Author:
Morgenbesser Sharon D.
Reference126 articles.
1. http://www.cancer.gov/cancertopics/types/prostate
.
2. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routesq. Clin Cancer Res. 2009;15:3251–5.
3. Van Poppel H, Joniau S, Van Cleynenbreugel B, Mottaghy FM, Oyen R. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Prostate Cancer Prostatic Dis. 2009;12:116–23.
4. Andriole GL, Crawford ED, Grubb III RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Eng J Med. 2009;360:1310–9.
5. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized european study. N Eng J Med. 2009;390:1320–8.